Claro Advisors LLC Acquires 57,511 Shares of Becton, Dickinson and Company (NYSE:BDX)

Claro Advisors LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2,053.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 60,312 shares of the medical instruments supplier’s stock after purchasing an additional 57,511 shares during the period. Becton, Dickinson and Company makes up 1.4% of Claro Advisors LLC’s portfolio, making the stock its 11th biggest position. Claro Advisors LLC’s holdings in Becton, Dickinson and Company were worth $14,541,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of BDX. Sound Income Strategies LLC boosted its stake in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $45,000. Abound Wealth Management boosted its stake in shares of Becton, Dickinson and Company by 96.0% in the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares in the last quarter. Tributary Capital Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at $49,000. Finally, Chilton Capital Management LLC boosted its stake in shares of Becton, Dickinson and Company by 1,233.3% in the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.2 %

Shares of NYSE:BDX traded up $0.46 during trading on Friday, hitting $240.79. 118,185 shares of the company’s stock were exchanged, compared to its average volume of 1,389,496. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $262.23. The firm has a 50-day moving average price of $236.86 and a two-hundred day moving average price of $235.28. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm has a market cap of $69.59 billion, a P/E ratio of 52.93, a PEG ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same quarter in the previous year, the business earned $2.96 EPS. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. Equities analysts predict that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.58%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on BDX shares. Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Raymond James reduced their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, Stifel Nicolaus upped their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.